Q-omics provides the consensus-scored AKAP11 profile across patient tissues and cancer cell-line models. AKAP11 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AKAP11 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, AKAP11 RNA expression shows 21,622 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where AKAP11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKAP11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKAP11 survival associations across molecular data types. AKAP11 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKAP11 RNA expression–survival associations across cancer types. High AKAP11 expression shows unfavorable associations in CESC, OV and BLCA, but favorable associations in KIRC, LGG and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AKAP11 RNA expression.
This table summarizes AKAP11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for AKAP11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKAP11 shows lower tumor expression in LUSC, KICH, UCEC, LUAD and THCA and higher tumor expression in HNSC. The HNSC box plot shows higher AKAP11 RNA expression in tumor versus normal tissue (log2 FC = +0.545, t-test p < 0.001).
This table shows molecular features associated with AKAP11 in patient tissues and cancer cell lines. In patient samples, AKAP11 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, AKAP11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
